Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2026 07:05 ET | Source: Longeveron

Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease

Longeveron reports new data analysis for its stem cell therapy laromestrocel in mild Alzheimer's disease at AAIC 2026.
July 06, 2026 16:05 ET | Source: Longeveron

Longeveron® Appoints Marie Washburn as Chief Financial Officer

Marie Washburn appointed CFO at Longeveron.
June 18, 2026 09:20 ET | Source: Longeveron

New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)

Longeveron stem cell therapy Phase 2a clinical data in Alzheimer's disease selected for poster presentation at 2026 AAIC.
June 09, 2026 09:20 ET | Source: Longeveron

Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)

Longeveron (LGVN) granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).
June 04, 2026 09:15 ET | Source: Longeveron

Longeveron to Present at BIO International Convention 2026

Longeveron will present at BIO 2026. CEO, CFO & BD will host meetings to explore partnership opportunities for its 4 stem cell therapy developmet programs.
May 20, 2026 16:05 ET | Source: Longeveron

Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities

Longeveron CEO issues 2026 Letter to Stockholders.
May 13, 2026 16:05 ET | Source: Longeveron

Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

Longeveron (LGVN), developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, reported 1Q26 financial results.
May 11, 2026 09:10 ET | Source: Longeveron

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron announces Data Monitoring Committee for Phase 2b clinical trial in HLHS completed a risk-benefit assessment and recommended continuation.
May 08, 2026 16:05 ET | Source: Longeveron

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron announced that a constructive Type C meeting with the U.S. FDA was held to discuss the ongoing development of laromestrocel in HLHS.
May 05, 2026 16:15 ET | Source: Longeveron

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Longeveron will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026.